ACVR1C

Across TCGA pan-cancer cohorts, ACVR1C Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated ACVR1C data layer compared with 17 for mass-spec protein.

The strongest signal is observed in ovarian serous cystadenocarcinoma (OV), where higher ACVR1C Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated ACVR1C expression acts as an unfavorable survival marker, although some lineages such as UCEC and SKCM show a favorable association.

OV, UCEC, and STAD are the cancer types where ACVR1C Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
OV	OS	Median	II,III,IV	0.180	0.844	<.001	36	view →
UCEC	DFS	Median	All	1.000	0.625	.006	30	view →
STAD	OS	Median	II,III,IV	0.501	0.660	.006	10	view →
SKCM	DFS	Median	All	0.953	0.716	.021	5	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

ACVR1C–OV (OS)

Open the OV breakdown →